[Investigation of the dopamine dysregulation hypothesis of schizophrenia with neuroimaging techniques].
The most elaborated biochemical concept of schizophrenia is the dopamine hypothesis. However, this classical theory is based on indirect observations. It has recently become possible to study this theory directly by means of advanced functional neuroimaging techniques, the development of specific radioligands and study protocols that are eligible to monitor dynamic changes in the neurotransmitter systems. According to the early concept, the essence of schizophrenia is the hyperactivity of the dopamine system. Nevertheless, this idea has gone through many modifications. In accordance with the modified dopamine hypothesis, the cognitive deficit and negative symptoms are related to the hypoactivity of the dorsolateral prefrontal cortex while the acute phases of the disease associates with hyperactivity of the ventral striatal elements of the dopaminergic system. Between these dysfunctions there is causality via their exuberant connections. Beyond that, the interactions between the prefrontal and striatal anomalies implicate the involvement of other neurotransmitters than dopamine. Observations from model psychosis induced by N-methyl-D-aspartate antagonists and in vivo neuroimaging investigations in humans support primarily the role of glutamatergic system. Our developing knowledge about the neurochemical mechanism of schizophrenia can significantly affect therapeutic strategies as well.
Szegedi Tudományegyetem, Pszichiátriai Klinika 6725 Szeged, Semmelweis u. 6. szekeres@nepsy.szote.u-szeged.hu
György
G
Szekeres
László
L
Pávics
Zoltán
Z
Janka
D000661:Amphetamine / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D015259:Dopamine Agents / Q000378:metabolism; D018690:Excitatory Amino Acid Agonists / Q000378:metabolism; D006801:Humans; D008279:Magnetic Resonance Imaging; D016202:N-Methylaspartate / Q000037:antagonists & inhibitors / Q000378:metabolism; D017397:Prefrontal Cortex / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology; D019275:Radiopharmaceuticals; D011954:Receptors, Dopamine / Q000378:metabolism*; D012559:Schizophrenia / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology; D014055:Tomography, Emission-Computed; D015899:Tomography, Emission-Computed, Single-Photon
D015259:Dopamine Agents; D018690:Excitatory Amino Acid Agonists; D019275:Radiopharmaceuticals; D011954:Receptors, Dopamine; D016202:N-Methylaspartate; D000661:Amphetamine; D004298:Dopamine